Francis Burrows
CIK: 0002051119
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Kura Oncology, Inc.
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 24, 2026KURA
Kura Oncology, Inc.
Exercise(M)Direct30K shares at avg. $6.15$185K - Sep 24, 2026KURA
Kura Oncology, Inc.
Sale(S)Direct20.7K shares at avg. $10.83$225K - Jan 27, 2026KURA
Kura Oncology, Inc.
Sale(S)Direct1.3K shares at avg. $8.46$11K - Jan 2, 2026KURA
Kura Oncology, Inc.
Award(A)DirectOption to purchase common stock
185K shares- - Dec 18, 2025KURA
Kura Oncology, Inc.
Exercise(M)Direct35K shares at avg. $4.80$168K - Dec 18, 2025KURA
Kura Oncology, Inc.
Sale(S)Direct23.7K shares at avg. $9.78$232K - Jan 28, 2025KURA
Kura Oncology, Inc.
Sale(S)Direct1.3K shares at avg. $7.87$10K - Jan 28, 2025KURA
Kura Oncology, Inc.
Sale(S)Direct846 shares at avg. $7.87$7K - Jan 2, 2025KURA
Kura Oncology, Inc.
Award(A)DirectOption to purchase common stock
185K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 24, 2026 | KURA Kura Oncology, Inc. | Exercise(M) | 30,000 | $6.15 | $184,500 | Direct |
| Sep 24, 2026 | KURA Kura Oncology, Inc. | Sale(S) | 20,726 | $10.83 | $224,514 | Direct |
| Jan 27, 2026 | KURA Kura Oncology, Inc. | Sale(S) | 1,311 | $8.46 | $11,092 | Direct |
| Jan 2, 2026 | KURA Kura Oncology, Inc. | Award(A) Option to purchase common stock | 185,000 | - | - | Direct |
| Dec 18, 2025 | KURA Kura Oncology, Inc. | Exercise(M) | 35,000 | $4.80 | $168,000 | Direct |
| Dec 18, 2025 | KURA Kura Oncology, Inc. | Sale(S) | 23,726 | $9.78 | $231,931 | Direct |
| Jan 28, 2025 | KURA Kura Oncology, Inc. | Sale(S) | 1,320 | $7.87 | $10,391 | Direct |
| Jan 28, 2025 | KURA Kura Oncology, Inc. | Sale(S) | 846 | $7.87 | $6,660 | Direct |
| Jan 2, 2025 | KURA Kura Oncology, Inc. | Award(A) Option to purchase common stock | 185,000 | - | - | Direct |
1-9 of 9 transactions
About Burrows Francis
Burrows Francis (SEC CIK 0002051119) files insider reports with the SEC as Chief Scientific Officer of Kura Oncology, Inc. (KURA).
Signal8 holds 7 ownership filings by Burrows Francis (1 Form 3, 6 Form 4), filed between Jan 7, 2025 and Sep 25, 2026. Those filings report 9 transactions, from Jan 2, 2025 to Sep 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Burrows Francis's filings is in SAN DIEGO, CA.
Recent filings by Burrows Francis
- Sep 24, 2026: Option exercise of KURA shares (Form 4, code M).
- Sep 24, 2026: Open-market sale of KURA shares (Form 4, code S).
- Jan 27, 2026: Open-market sale of KURA shares (Form 4, code S).
- Jan 2, 2026: Grant or award of KURA derivative securities (Form 4, code A).
- Dec 18, 2025: Option exercise of KURA shares (Form 4, code M).
Other insiders filing for Kura Oncology, Inc. (KURA)
- Bair Teresa Brophy, Chief Legal Officer
- FORD KATHLEEN, Chief Operating Officer
- Leoni Mollie, Chief Medical Officer
- DOYLE THOMAS JAMES, SVP, Finance & Accounting
- Powl Brian T., Chief Commercial Officer
- Fulk Jennifer, Chief Financial Officer